| Description | MK-3328 has a high affinity for β-Amyloid (IC50:10.5 nM), and can be used as a candidate PET ligand for clinical assessment of β-amyloid plaque load. MK-3328 is a potential treatment for Alzheimer's disease. |
| In vitro | MK-3328 displays amyloid binding potency balanced with low levels of nonspecific binding.[1] |
| In vivo | In normal rhesus monkey positron emission tomography (PET) imaging studies, [18F]MK-3328 demonstrates favorable kinetics, exhibiting high brain uptake, and good washout.[2] |
| Target activity | β-Amyloid:10.5 nM |
| molecular weight | 268.25 |
| Molecular formula | C14H9FN4O |
| CAS | 1201323-97-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Slightly soluble |
| References | 1. Harrison ST, et al. Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328. ACS Med Chem Lett. 2011;2(7):498-502. |